Article info
PDFOriginal articles
Clinical science
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
- Correspondence to S James Talks, Department of Ophthalmology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne NE1 4LP, UK; James.Talks{at}nuth.nhs.uk
Citation
Measuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degeneration
Publication history
- Accepted August 18, 2012
- First published September 21, 2012.
Online issue publication
March 22, 2016
Article Versions
- Previous version (22 March 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions